Menu Close Call 1-800-CEDARS-1 toggle search form Close
Kathrin S. Michelsen, PhD

Kathrin S. Michelsen, PhD

Research
No patient rating & comments. Why?
  • The doctor practices in an office or specialty that we currently do not survey.
  • The doctor has not yet received the minimum number of patient satisfaction surveys (30) to be eligible for display.
Kathrin S. Michelsen, PhD
No patient rating & comments. Why?
  • The doctor practices in an office or specialty that we currently do not survey.
  • The doctor has not yet received the minimum number of patient satisfaction surveys (30) to be eligible for display.

Kathrin S. Michelsen, PhD

Research
No patient rating & comments. Why?
  • The doctor practices in an office or specialty that we currently do not survey.
  • The doctor has not yet received the minimum number of patient satisfaction surveys (30) to be eligible for display.
Kathrin S. Michelsen, PhD

Kathrin S. Michelsen, PhD

Research
Back to Top

Languages

  • English,

Gender

Female

Experience

20 Years

Experience

Specialties

Area in which a healthcare provider is highly trained and often board certified.

1

  • Research

Programs

Cedars-Sinai clinical programs this provider is part of:

1

Research Areas

The research of Kathrin Michelsen, PhD, focuses on the role of innate and adaptive immunity in the development of intestinal inflammation. Animal models are used to elucidate the molecular mechanism of dysregulated immune responses that lead to chronic inflammation of the mucosa. The mouse models of intestinal inflammation are used as pre-clinical models to conduct laboratory studies that will identify molecules for eventual therapeutic intervention.

Titles

  • Assistant Professor, Medicine
  • Assistant Professor, Medicine
  • Research Scientist, Inflammatory Bowel Disease Center

Education & Training

  • Humboldt University of Berlin

    Degrees - Completed 2002

Achievements

  • 4

    Awards and Honors

  • 7

    Publications

Awards and Honors

  • American Association of Immunologists
  • UCLA Chancellor's Award for Postdoctoral Research
  • Society for Mucosal Immunology
  • International Endotoxin and Innate Immunity Society

Publications

A full list of this provider’s research publications can be found on their research profile or PubMed.

  • Michelsen KS, Wong MH, Ko B, Thomas LS, Dhall D, Targan SR. HMPL-004 (Andrographis paniculata extract) prevents development of murine colitis by inhibiting T-cell proliferation and TH1/TH17 responses. Inflamm Bowel Dis. 2013;19(1):151-164.
  • Takedatsu H, Michelsen KS, Wei B, Landers CJ, Thomas LS, Dhall D, Braun J, Targan SR. TL1A (TNFSF15) regulates the development of chronic colitis by modulating both T-helper 1 and T-helper 17 activation. Gastroenterology. 2008;135(2):552-567.
  • Chen S, Wong MH, Schulte DJ, Arditi M, Michelsen KS. Differential expression of Toll-like receptor 2 (TLR2) and responses to TLR2 ligands between human and murine vascular endothelial cells. J Endotoxin Res. 2007;13(5):281-296.
  • Prehn JL, Thomas LS, Landers CJ, Yu QT, Michelsen KS, Targan SR. The T cell costimulator TL1A is induced by FcgammaR signaling in human monocytes and dendritic cells. J Immunol. 2007;178(7):4033-4038.
  • Michelsen KS, Wong MH, Shah PK, Zhang W, Yano J, Doherty TM, Akira S, Rajavashisth TB, Arditi M. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci U.S.A. 2004;101(29):10679-10684.
  • Michelsen KS, Arditi M. Toll-like receptors and innate immunity in gut homeostasis and pathology. Curr Opin Hematol. 2007;14(1):48-54.
  • Michelsen KS, Arditi M. Toll-like receptor signaling and atherosclerosis. Curr Opin Hematol. 2006;13(3):163-168.
View Publications on PubMed